Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - The lancet …, 2011 - thelancet.com
Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban… - The Lancet …, 2011 - pubmed.ncbi.nlm.nih.gov
Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
[引用][C] Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A …
J Garcia-Donas, E Esteban… - The Lancet …, 2011 - produccioncientifica.ucm.es
Single nucleotide polymorphism associations with response and toxic effects in patients with
advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational …
advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational …
[PDF][PDF] Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - Lancet Oncol, 2011 - academia.edu
Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - The Lancet …, 2011 - thelancet.com
Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - The Lancet …, 2011 - Elsevier
BACKGROUND: Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - The Lancet …, 2011 - europepmc.org
Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - The Lancet …, 2011 - infona.pl
Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell carcinoma, but some
patients do not respond or need dose reductions due to toxicity. Because there are no …
patients do not respond or need dose reductions due to toxicity. Because there are no …
[引用][C] Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - The Lancet …, 2011 - cir.nii.ac.jp
Single nucleotide polymorphism associations with response and toxic effects in patients with
advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational …
advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational …
[PDF][PDF] Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a …
J Garcia-Donas, E Esteban, LJ Leandro-García… - Lancet Oncol, 2011 - academia.edu
Background Sunitinib is a tyrosine kinase inhibitor with proven efficacy in renal-cell
carcinoma, but some patients do not respond or need dose reductions due to toxicity …
carcinoma, but some patients do not respond or need dose reductions due to toxicity …